Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

African Union drops plans to buy Covid-19 vaccines from the Serum Institute of India

The AU is exploring purchasing jabs from US firm Johnson & Johnson

Joe Middleton
Thursday 08 April 2021 08:12 EDT
Comments
(AP)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

The African Union (AU) has today dropped plans to secure Covid-19 vaccines from the Serum Institute of India.

Instead the AU is exploring purchasing jabs from US firm Johnson & Johnson, said the head of the Africa Centres for Disease Control and Prevention.

The institute will still supply the AstraZeneca vaccine to Africa through the COVAX vaccine-sharing facility that is being run by the World Health Organisation (WHO).

The COVAX scheme is designed to get vaccine supplies to less wealthy countries. The WHO last month published a list of the first vaccine allocations under the project.

However the AU will seek additional supplies from Johnson & Johnson, John Nkengasong told reporters on Thursday.

Read more:

It comes just a day after European and British medicine regulators said they had found possible links between AstraZeneca’s vaccine and reports of very rare cases of brain blood clots.

However they reaffirmed the vaccine’s importance in protecting people and said the benefits of the inoculation far outweigh the risks.

Mr Nkengasong said the possible blood clot link had nothing to do with the AU’s decision.

The bloc of 55 member states shifted its efforts to the Johnson & Johnson vaccine, he said, citing the deal signed last week to secure up to 400 million doses beginning in the third quarter of this year.

“It was just a clear understanding of how not to duplicate efforts with the Serum Institute, so that we compliment each other rather than duplicate efforts,” he added.

Additional reporting by Reuters

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in